A 64-year-old man underwent a radical cystoprostatectomy for intravesical bacillus Calmette-Guerin (BCG) therapy-resistant, recurrent muscle invasive transitional cell carcinoma (TCC) of the urinary bladder. He had a history of left radical nephroureterectomy for a papillary TCC of the left ureter 10 months ago. On microscopic examination, not only multifocal residual papillary TCCs in the urin...

Dengue viruses (DENVs) are among the most rapidly and efficiently spreading arboviruses. WHO recently estimated that about half of the world's population is now at risk for DENV infection. There is no specific treatment or vaccine available to treat or prevent DENV infections. Here, we report the development of a novel dengue nanovaccine (DNV) composed of UV-inactivated DENV-2 (UVI-DENV) and My...

INTRODUCTION The aim of this study was to examine the efficacy and safety of intravesical Bacillus Calmette-Guerin (BCG) in the treatment of refractory interstitial cystitis (IC). MATERIALS AND METHODS Thirteen patients with refractory IC were enrolled in the study. They were scheduled to receive 6 weekly courses of treatment with intravesical BCG. Variables including the frequency, nocturia,...

Background: Lymphadenitis is the most common complication of BCG vaccination in children. Interferon-gamma (IFN-γ) plays a key role in immune response to Mycobacterial infections. In this study, the relationship of serum levels of IFN-γ and its receptor (CD119) to development of Bacillus Calmette Guerin (BCG) axillary lymphadenopathy was investigated. <em...

In 2014, I was on the Board of Directors of the Society of Urologic Oncology (SUO) when Merck announced having shortages of Tice strain Bacillus Calmette Guerin (BCG), a critical “drug” for treating intermediate and particularly high risk non-muscle invasive (NMI) urothelial cancer (UC) of the bladder, including carcinoma-in-situ (CIS) and high-grade (HG), stage Ta and T1 disease after transure...

Stlmmary The ~rrent vacdne against tuberculosis, Mycobacterium boris strain baciUe Calmette-Guerin (BCG), offers potential advantages as a live, innately immunogenic vaccine vehicle for the expression and delivery of protective recombinant antigens (Stover, C. K., V. F. de la Cruz, T. R. Fuerst, J. E. Burlein, L. A. Benson, L. T. Bennett, G. P. Bansal, J. F. Young, M. H. Lee, G. F. Hatfull et a...

The current vaccine against tuberculosis, Mycobacterium bovis strain bacille Calmette-Guerin (BCG), offers potential advantages as a live, innately immunogenic vaccine vehicle for the expression and delivery of protective recombinant antigens (Stover, C.K., V.F. de la Cruz, T.R. Fuerst, J.E. Burlein, L.A. Benson, L.T. Bennett, G.P. Bansal, J.F. Young, M.H. Lee, G.F. Hatfull et al. 1991. Nature ...

BACKGROUND Bacillus Calmette-Guérin (BCG) vaccination is performed as a part of expanded Programme of Immunization (EPI). Suppurative lymphadenitis is the common complication of BCG vaccination. The optimum treatment for this complication is debated. METHODS All cases of BCG lymphadenitis presenting to pediatric surgical service over a 17-year study period were reviewed to determine the optim...